News & Updates
Filter by Specialty:
Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer
The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.
Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer
21 Jun 2022
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
20 Jun 2022
Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
Insulin resistance in young people with obesity is positively associated with an atherogenic lipoprotein/lipid profile and carotid intima-media thickness (cIMT), regardless of their glucose tolerance status, suggests a study.
Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
20 Jun 2022
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.